廣信材料(300537.SZ):後續許多正在計劃上光伏BC電池產能的光伏企業都在與公司對接
格隆匯1月7日丨廣信材料(300537.SZ)在投資者關係活動上表示,隨着光伏BC電池產能和銷量快速增長,公司光伏BC電池絕緣膠作為BC電池必備品將率先受益,該成品是廣信材料率先實現批量銷售且目前仍舊處於遙遙領先的市場佔有率絕對優勢,除了現在市場上的主要光伏BC電池龍頭企業的穩定供貨和放量,後續許多正在計劃上光伏BC電池產能的光伏企業都在與公司對接,公司在此領域先發優勢和行業積累明顯,將成為公司現階段重要第二增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.